My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
Expression of FOXP3, CD68 and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma is Predictive of outcome. J Clin Oncol (2013) 31(2):256-62. PMID: 23045593
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA (2009) 106(15):6250-5. PMID: 19332800
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 118(7):2427-37. PMID: 18551193
SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. Blood (2008) 112(2):394-7. PMID: 18434611
The research interest of my group focuses on immunological approaches to the treatment of haematological cancers. In particular, we are interested in understanding:
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes Casado P, Rio-Machin A, Miettinen JJ et al. Signal Transduction and Targeted Therapy (2023) 8(7)
Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma. Gribben J, Palomba ML, Patel AR et al. Blood Adv (2023) 7(2) 2494-2495
Lack of reproducibility of histopathological features in MYC-rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium Natkunam Y, de Jong D, Farinha P et al. Histopathology (2023) 82(7) 1105-1111
An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA Rejeski K, Greco R, Onida F et al. HemaSphere (2023) 7(7)
O20 TARGETING THE DEFECTIVE COA PATHWAY TO IMPROVE ERYTHROPOIESIS IN SF3B1-MUTANT MDS-RS PATIENTS Philippe C, Mian S, Maniati E et al. Leukemia Research (2023) 128(10) 107133
Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment Stevens WBC, Los-De Vries GT, Langois-Jacques C et al. HemaSphere (2023) 7(7) E863
PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion Taylor JG, Truelove E, Clear A et al. Haematologica (2023) 108(7) 1068-1082
A Lack of Diversity, Equity, and Inclusion in Clinical Research Has Direct Impact on Patient Care El-Galaly TC, Gaidzik VI, Gaman MA et al. HemaSphere (2023) 7(7) E842
Pharmacologic Features of Drugs Targeting Bruton's Tyrosine Kinase ( BTK ) McCay and J, Gribben JG (2023) (10) 268-277
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma Bewicke-Copley F, Korfi K, Araf S et al. Blood Advances (2023) 7(7) 845-855For additional publications, please click here
Group Leaders in the Centre
Dr Andrejs Braun, Dr Jeff Davies, Dr Gabriella Ficz, Professor Kamil R. Kranc, Dr Sergey Krysov, Dr Rifca Le Dieu, Dr Kevin Rouault-Pierre, Dr John Riches, Dr Bela Wrench
Clinical Research Fellows
Dr Jennifer Edelmann, Dr Robin Sanderson, Dr Joseph Taylor, Dr Edward Truelove
I hold the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. My doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. I continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.
In 1992, I was appointed to the Faculty at Harvard Medical School, where I remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. I am a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.